A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  European Journal of Cancer and Clinical Oncology

• Publication date

  1985-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0277-5379(85)90040-9PMID 3891362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer

  2004cited by this paper
• cis-platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma

  2004cited by this paper
• A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

  1983cited by this paper
• Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

  1983cited by this paper
• High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.

  1982cited by this paper
• Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.

  1982cited by this paper
• Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa‐CAF)

  1981cited by this paper
• Phase II clinical trial of VP-16-213 in ovarian cancer.

  1981cited by this paper
• Epithelial carcinoma of the ovary: current strategies.

  1981cited by this paper
• Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5‐fluorouracil and dactinomycin or with the combination of cytoxan, 5‐fluorouracil and dactinomycin

  1980cited by this paper
• Acute non‐lymphocytic leukemia in patients with ovarian carcinoma following long‐term treatment with treosulfan (=dihydroxybusulfan)

  1980cited by this paper
• Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

  1979cited by this paper
• The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).

  1979cited by this paper
• Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.

  1979cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper
• Single Agent Vs Combination Chemotherapy in The Treatment of Ovarian Cancer

  1977cited by this paper
• Single agent vs combination chemotherapy in the treatment of ovarian cancer.

  1977cited by this paper
• Management of ovarian carcinoma. Current concepts and future prospects (first of two parts).

  1976cited by this paper

• Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

  2018cites this paper
• Antitumor activity of treosulfan against human breast carcinomas

  2004cites this paper
• High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer

  2004cites this paper
• Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma

  2003cites this paper
• A systematic overview of chemotherapy effects in ovarian cancer.

  2001cites this paper
• A Systematic Overview of Chemotherapy Effects in Ovarian Cancer

  2001cites this paper
• Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.

  1999cites this paper
• The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.

  1998cites this paper
• The role of second-look laparotomy in the long-term survival in ovarian cancer.

  1997cites this paper
• Impact of doxorubicin on survival in advanced ovarian cancer.

  1995cites this paper
• Antitumor activity of treosulfan in human lung carcinomas

  1995cites this paper
• Treatment of advanced epithelial ovarian cancer: past, present and future.

  1995cites this paper
• The search for optimal chemotherapy for advanced epithelial ovarian cancer.

  1995cites this paper
• Clinical and prognostic features of advanced ovarian carcinoma.

  1993cites this paper
• Dose intensity analysis in advanced ovarian cancer patients.

  1993cites this paper
• Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy.

  1992cites this paper
• Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

  1992cites this paper
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  1991cites this paper
• A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.

  1990cites this paper
• Four-year analysis of platinum and anthracycline combination for ovarian cancer.

  1989cites this paper
• A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives.

  1989cites this paper
• Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.

  1988cites this paper
• [Therapeutic effectiveness of various combination chemotherapy protocols in advanced epithelial ovarian cancer].

  1986cites this paper